TABLE OF CONTENTS
International Transfer Pricing in the Ethical Pharmaceutical Industry Second edition

SUMMARY OF SALIENT POINTS
Importance and Competitiveness of the Ethical Pharmaceutical Industry
Government Intervention
Research and Development (R&D)
Risks and Cost of R&D
Need to Recover Current R&D from Current Sales of All Products
Marketing
Marketing and Risk
Scientific and Medical Information: Integral part of an Ethical Pharmaceutical Product
Government Price Controls
Pricing of Ethical Medicines
Transfer Prices – Transfer Conditions
Arm’s Length Principle
Methods of Arriving at Arm’s Length Prices
Transfer Prices for Services and Technology
Practice of Companies in Determining Transfer Prices
Principle Considerations for Determining Transfer Prices
Motivation of National Management
Persistence of Transfer Prices over Time
Geographical Consistency, or Otherwise, of Transfer Prices
Effect of Government Price Controls on Transfer Prices
Effect of Currency Fluctuations
Tax Considerations in Transfer Pricing
Intra-Multinational Group Negotiations of Transfer Prices
Effect of Tax Authorities’ Pressure on Transfer Prices
General Approach of Tax Authorities to Companies’ Transfer Pricing
Burden of Proof
Usefulness of OECD Guidelines
Penalties
Corresponding Adjustments
Testing and Defending Transfer Prices on the Arm’s Length Basis
Comparable Uncontrolled Prices
Generic Products
Parallel Imports and Pirate Copies, counterfeits
Cost-based Approaches
Resale Price Method
Choice of Method
Basket Approach
Global or Unitary or Profit-splitting Approaches
US Regulations on Transfers of Technology
General Need for Reasonableness and Flexibility
PART 1
INTRODUCTION
1 Origin, Purpose, Scope and Basis of Report
2 What is meant by the “Ethical Pharmaceutical Industry”?

PART 2
CHARACTERISTICS OF THE ETHICAL PHARMACEUTICAL INDUSTRY

CHAPTER 1 Governing Factors
1.1 Introductory
1.2 General
1.3 From the General Public’s Point of View
1.4 From the Investors’ Point of View
1.5 From the Companies’ Point of View

CHAPTER 2 Special Factors Affecting the Companies’ Operations
2.1 Competitiveness
2.1.1 Competition in General
2.1.2 Competition from Generics
2.1.3 Competition through Arbitrage from Re- and Parallel Importers
2.1.4 Competition from Pirate or Counterfeit Products
2.2 Research and Development
2.2.1 Importance of R&D
2.2.2 Brief Description of Research and Development
2.2.2.1 Research
2.2.2.2 Development
2.2.2.3 Effect of Differences between Research and Development
2.2.2.4 Intertwinement of Research and Development
2.2.3 New Chemical Entities
2.2.4 Unpredictability of R&D Results
2.2.5 R&D Expenditure
2.2.6 Time Taken to Develop New Chemical Entities
2.2.7 Proportion of R&D Costs to Turnover
2.2.8 Payment Out of Current Receipts
2.2.9 R&D Costs as a Percentage of Product Sales in 1989
2.2.10 Intellectual Property Rights
2.2.11 Patents
2.2.12 Trademarks, Brands and Domain Names
2.3 Multitude of High Risks
2.4 Marketing
2.4.1 Marketing Intangibles
2.4.2 Scientific and Medical Support
2.5 The Provision of a Service
2.6 The Need for Sufficient Profits
2.7 Government Intervention
CHAPTER 3 Structures and Modes of Operation of Multinational Enterprises in the Ethical Pharmaceutical Industry

3.1 General
3.2 Structures
3.2.1 The Importance of the Centre
3.2.2 Wholly-owned Subsidiaries
3.3 Modes of Operation
3.3.1 General
3.3.2 Manufacturing
3.3.3 Marketing
3.3.4 Research and Development
3.3.5 Intra-Multinational Group Services
3.3.6 Central Administration, Co-ordination and Control
3.4 Complexity of Structures
3.5 Relative Costs of Various Activities
3.5.1 Manufacturing Costs
3.5.2 Research and Development Cost
3.5.3 Marketing Costs

PART 3
HOW MARKET PRICES ARE DETERMINED
1.1 Relevance of Market Pricing to Transfer Pricing 93
1.2 Price Bases – General 93
1.3 Relevance of Prices of Competing Products 94
1.4 Relevance of Customers’ Perception of Value 95
1.5 Relevance of Costs 96
1.6 Other Pricing Factors 97
1.6.1 Target Price 98
1.6.2 Variation of Price from Market to Market 99
1.6.3 Effect of Government Price Controls 100

PART 4
TRANSFER PRICING IN THE ETHICAL PHARMACEUTICAL INDUSTRY
CHAPTER 1 General
1.1 Neutrality of the Terms “Transfer Price” and “Transfer Pricing” 103
1.2 Ways in Which the Term “Transfer Price” is Used 103
1.2.1 Interest of Governments in Transfer Prices 104
1.2.2 Incidence of Pharmaceutical Transfer Pricing 104
1.2.3 Amounts of Money Involved in Intra-Multinational Group Transfers 104
1.2.4 Need for Acceptable Transfer Prices 105
1.2.5 The OECD and UN Models 105
1.2.6 Methods of Testing for Arm’s Length Prices 106
1.2.7 Superiority of Arm’s Length Principle 107
1.2.8 Difficulty of Determining Arm’s Length Prices 108
CHAPTER 2 The Determination of Transfer Prices by Ethical Pharmaceutical Group Companies

2.1 General Background 109
2.1.1 Negotiation of Transfer Prices 110
2.1.1.1 Considerations Having a Bearing on the Determination of Transfer Prices 112
   (i) National Profit Considerations 112
   (ii) Motivating Group Company Management 113
   (iii) Minority Holdings, etc. 113
   (iv) Requirements of Social Legislation, etc. 113
   (v) Demonstrating Reasonableness of Transfer Prices 113
2.1.1.2 Factors Taken into Account in Determining Transfer Prices 113
2.1.1.3 Basket Transfer Pricing 117
2.1.1.4 Persistence and Review of Transfer Prices 117
2.1.2 Geographical Consistency or Variation in Transfer Prices 118
2.1.3 Variation of Transfer Price according to Product Form 121
2.1.4 Effect of Government Price Controls on Transfer Prices 122
2.1.5 Currency Fluctuations and Transfer Prices 123
2.1.6 Tax Considerations 125
2.2 Transfer Pricing of Products 127
2.2.1 Resale Minus Based Pricing 127
2.2.2 Comparable Uncontrolled Prices 129
2.2.3 Cost-based Transfer Pricing 130
2.2.4 Other Methods 131
2.3 Transfer Pricing of Intra-Multinational Group Services 131
2.3.1 General 131
2.3.2 Services Charged for Directly 132
2.3.3 Services Not Specifically Charged for 132
2.3.4 Influence of Tax Authorities 133
2.3.5 Contract R&D and Manufacturing 133
2.4 Transfer Pricing of Results of R&D 134
2.5 Transfer Pricing of Intangibles 135
2.6 Evaluation of Royalty Rates 137

PART 5
DISCUSSION OF THE GENERAL APPROACH OF TAX AUTHORITIES
1.1 Basic Considerations 139
1.2 Disagreement with Competent Authorities 143
1.3 Corresponding Adjustments 144

PART 6
TESTING AND DEFENDING TRANSFER PRICES ON THE ARM'S LENGTH BASIS
CHAPTER 1 General
1.1 Traditional Transaction and Other Methods
1.2 Global or Unitary Approaches
1.2.1 Description
1.2.2 Criticism
1.2.3 Use of Global or Unitary Approach for Preliminary Appraisals
1.2.4 Use in Relation to Subordinate Jurisdictions
1.2.5 OECD Attitude
1.3 Profit Split Approaches and Functional Analysis

CHAPTER 2 Testing and Defending Transfer Prices of Goods
2.1 Resale Minus Method
2.2 Comparable Uncontrolled Prices
2.2.1 General
2.2.2 Generic Products
2.2.3 Parallel Imports
2.2.4 Pirate, Counterfeit Products
2.2.5 OECD Comments
2.3 Cost-based Approaches
2.4 Other Methods
2.4.1 Global Allocation of Profits
2.4.2 Profit Splits
2.4.3 Basket Pricing

CHAPTER 3 Testing and Defending Transfer Prices of Intra-Multinational Group Services
3.1 General
3.1.1 Specific Services
3.1.2 Generalized Services
3.2 R&D Services
3.2.1 OECD Comment
3.2.2 Cost-sharing
3.2.3 Contract R&D

CHAPTER 4 Testing and Defending Transfer Pricing of Technology and Other Intangibles
4.1 General
4.2 Commensurate with Income Royalties
4.2.1 Methods
4.2.1.1 US White Paper Rules of 1988
4.2.1.2 Rules in US Draft, Temporary and Final Regulations
4.2.2 Adjustability of Royalty Rate
4.2.2.1 US Proposals and Final Regulations
4.2.2.2 Lack of Evidential Basis for Proposals
4.2.2.3 Relaxations of Adjustability Rules
4.2.2.4 Conflict with Arm’s Length Principle

PART 7
GENERAL SUMMARY AND CONCLUSIONS
APPENDICES

APPENDIX A
THE RESEARCH AND DEVELOPMENT PROCESS
A.1 The Pharmaceutical Research and Development Pipeline
A.2 The Phases of R&D
A.2.1 A Summary of the Phases of a Clinical Trial Programme in the United Kingdom
A.2.2 Discovery and Development of a New Medicine
A.2.3 The Process of R&D in the US

APPENDIX B
COST OF DEVELOPING A NEW MEDICINE

APPENDIX C
TIME TO DEVELOP A NEW MEDICINE

APPENDIX D
R&D EXPENDITURE
D.1 Expenditure as a Proportion of Turnover
D.2 Comparison with Other Industries
D.2.1 R&D Expenditure for Various Industries in the UK
D.2.2 R&D Expenditure as Percentage of Turnover for Industries in Four Countries
D.3 Total Amounts of Expenditure on R&D Worldwide
D.4 Totals for Individual Multinational Groups
D.5 Multinational Groups' R&D Expenditure Growth
D.6 Capital Expenditure
D.7 Increasing Costs of R&D

APPENDIX E
ATTRIBUTION OF R&D COSTS TO INDIVIDUAL PRODUCTS

APPENDIX F
BLOCKBUSTERS

APPENDIX G
INTELLECTUAL PROPERTY RIGHTS AND LICENSING
G.1 Patents: Supra-national Developments
G.2 Patents: Limitations of Patent Protection
G.3 Patents: Patent Life Extension
G.4 Trademarks, Brands and Domain Names
G.4.1 Trademarks and Safety of Medicines
G.4.1.1 FDA – Process on Trademarks
G.4.1.2 EMEA – Process on Trademarks
G.4.2 Domain Names
G.5 Licensing

APPENDIX H
US TRANSFER PRICING OF INTANGIBLES
H.1 “Super-royalties”: “Commensurate with Income Royalties”
H.2 Types of Intangibles
H.3 US Proposals and Regulations – Intra-Multinational Group Licensing of Intangibles
H.4 Problems posed by the US proposals
H.4.1 Exact Comparables Method
H.4.2 Inexact Comparables Method
H.4.3 BALRM Method
H.5 Objections to BALRM method
H.6 Periodic Adjustments – “Super-royalties”, “Commensurate with Income Royalties”
H.7 General Nature of Licensing Agreements
H.8 Criticism of US Proposals Concerning Variability of Licence Fees
H.9 US Draft, Temporary and Final Regulations
H.10 Intangible Property
H.11 Comparable Profit Method
H.12 Periodic Adjustments of Royalty, etc., Rate
H.12.1 Exceptions to the Periodic Adjustment Rule
H.13 Practical Problems of the Comparable Profit Method
H.14 Conclusion

APPENDIX J
GOVERNMENT INTERVENTION
J.1 Price and Profit Controls, Reimbursement Limitations, Prescribing Controls, Imposed Discounts and Repayments, Expenditure Limitations etc.
J.2 Other Countries and Other Controls
J.3 Approval of Ethical Pharmaceutical Products for Marketing

APPENDIX K
MERGERS IN THE INDUSTRY

APPENDIX L
LOW-TAX AREAS: SPECIAL TAX RELIEFS AND FISCAL INCENTIVES IN CERTAIN COUNTRIES
L.1 Puerto Rico
L.2 Ireland
L.3 Singapore
L.4 France
L.5 Italy
L.6 OECD

APPENDIX M
BACKGROUND MATERIAL
M.1 History and Geography of the Research-based Pharmaceutical Industry
M.2 Pharmaceutical Output
M.3 Companies and Ownership
M.4 Markets
M.5 Consumption
M.6 Expenditures on Health and on Medicines
APPENDIX N
CUSTOMS DUTIES

APPENDIX O
GENERICS
O.1 Generic Names and Brand Names
O.2 Categories of Generics

APPENDIX P
SHAREHOLDING IN AFFILIATES
P.1 Major Pharmaceutical Groups' Shareholdings in their Affiliates

APPENDIX Q
STRATEGIC ALLIANCES
Q.1 Major Pharmaceutical Groups' Joint Ventures, Co-marketing arrangements and other Co-operations

APPENDIX R
OECD TRANSFER PRICING REPORTS AND MULTINATIONAL ENTERPRISES
R. 1 "The so-called ‘global’ methods"

APPENDIX S
COMPETITIVENESS

APPENDIX T
ILLUSTRATIVE FIGURES

APPENDIX U
METHODS OF DETERMINING ARM’S LENGTH PRICES
U1 United States Regulations
U2 German Transfer Pricing Principles
U3 1979 OECD Report Transfer Pricing and Multinational Enterprises
U4 1995 OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations
U5 1998 UK Transfer Pricing Legislation

APPENDIX V
HEALTH ECONOMICS

APPENDIX W
VISUALIZING CHARTS
W1 Transfer Pricing in the Pharmaceutical Industry is of a different nature than in other industries
W2 R&D Process for an Ethical Pharmaceutical Product
W3 Submissions and Approvals of New Active Substances
W4 Median Approval Time for New Active Substances
W5 Functional Analysis
W6 Cost Plus Method not Applicable!
W7 The Market Minus Method
W7.1 Transfer Price – Transfer Conditions
W8 Structure of Market Prices in Europe
W9 Pricing and Reimbursement Measures taken by European countries
W9.1 Average Time from Pricing and/or Reimbursement Application to Reimbursement
W10 International Reference Pricing in Europe
W11 Payment for reimbursable Ethical Pharmaceuticals in Europe
W12 Loan Manufacturing with Consignment Stocks
W13 OECD Member States’ Transfer Pricing
W13.1 Transfer Pricing – Documentation Requirements
W14 European Union Joint Transfer Pricing Forum
W15 Nation States still rule the World
W17 Structure of the Domain Name System
W18 Input/Output Analysis – Production & Sales Company

APPENDIX X
INDEX OF KEY WORDS AND PHRASES